Granted Patent
B2
US 12,187,741 · App. 17/246,143 · Granted Jan 7, 2025
Glycosidase inhibitors
Inventors:
Anna Quattropani (Rolle, CH); Santosh S. Kulkarni (Bangalore, IN); Awadut Gajendra Giri (Bangalore, IN)
Assignee:
Asceneuron SA
C07D513/04A61K31/454A61K31/496A61K31/497A61K31/498A61K31/501A61K31/506A61K31/517A61K31/519A61K31/5377A61K45/06C07D277/46C07D285/135C07D401/12C07D403/12C07D405/12C07D405/14C07D413/12C07D413/14C07D417/12C07D417/14C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure relates to compounds of formula (I) useful in the treatment of tauopathies and Alzheimer's disease wherein A, R, W, Q, n, and m are described herein.
Claims (1)
1. A compound, wherein the compound is (S)-1-(1-(Benzo[d][1,3]dioxol-5-yl)ethyl)piperazine:
Assignments (3)
RELEASE OF SECURITY INTEREST
Recorded Feb 23, 2023
From: KREOS CAPITAL VI (UK) LIMITED
To: ASCENEURON SA
Reel/Frame 062789/0477 →
SECURITY INTEREST
Recorded Mar 22, 2022
From: ASCENEURON SA
To: KREOS CAPITAL VI (UK) LIMITED
Reel/Frame 059337/0849 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 3, 2021
From: QUATTROPANI, ANNA; KULKARNI, SANTOSH S.; GIRI, AWADUT GAJENDRA
To: ASCENEURON SA
Reel/Frame 056109/0849 →
Priority Claims (1)
IN 2766/MUM/2014
· Aug 28, 2014
· national
Continuity (3)
Continuation
15507375
References Cited (290)
US 3299067A
· Gilbert et al.
· 1967
[cited by applicant]
US 3457263A
· Regnier et al.
· 1969
[cited by applicant]
US 3485757A
· Shapiro
· 1969
[cited by applicant]
US 3489757A
· Volker
· 1970
[cited by examiner]
US 4600025A
· Grigg et al.
· 1986
[cited by applicant]
US 5935974A
· Rae et al.
· 1999
[cited by applicant]
US 7582769B2
· Murray et al.
· 2009
[cited by applicant]
US 7666875B2
· Gallagher, Jr. et al.
· 2010
[cited by applicant]
US 8008326B2
· Borza et al.
· 2011
[cited by applicant]
US 8952166B2
· Ding et al.
· 2015
[cited by applicant]
US 9120781B2
· Li et al.
· 2015
[cited by applicant]
US 20070027328A1
· Aronhime et al.
· 2007
[cited by applicant]
US 20080300276A1
· Borza et al.
· 2008
[cited by applicant]
US 20100022517A1
· Richards et al.
· 2010
[cited by applicant]
US 20110053982A1
· Fay et al.
· 2011
[cited by applicant]
US 20110060012A1
· Meyers et al.
· 2011
[cited by applicant]
US 20220143042A1
· Quattropani et al.
· 2022
[cited by applicant]
CN 1791594A
· 2006
[cited by applicant]
CN 103435606
· 2013
[cited by applicant]
EP 2301936
· 2011
[cited by applicant]
EP 2687507
· 2014
[cited by applicant]
FR 1311316
· 1962
[cited by applicant]
JP 2010270034
· 2010
[cited by applicant]
WO WO1993021181
· 1993
[cited by applicant]
WO WO1997043279
· 1997
[cited by applicant]
WO WO1998046590
· 1998
[cited by applicant]
WO WO9921850
· 1999
[cited by applicant]
WO WO02094799
· 2002
[cited by applicant]
WO WO2003092678
· 2003
[cited by applicant]
WO WO2004002481
· 2004
[cited by applicant]
WO WO2004005293
· 2004
[cited by applicant]
WO WO2004022558
· 2004
[cited by applicant]
WO WO2004094380
· 2004
[cited by applicant]
WO WO2005110982
· 2005
[cited by applicant]
WO WO2006092049
· 2006
[cited by applicant]
WO WO2007008541A2
· 2007
[cited by applicant]
WO WO2007115077
· 2007
[cited by applicant]
WO WO2007135398
· 2007
[cited by applicant]
WO WO2007146122
· 2007
[cited by applicant]
WO WO2008012623
· 2008
[cited by applicant]
WO WO2008025170
· 2008
[cited by applicant]
WO WO2009011904
· 2009
[cited by applicant]
WO WO2009053373
· 2009
[cited by applicant]
WO WO2009131926
· 2009
[cited by applicant]
WO WO2010018868
· 2010
[cited by applicant]
WO WO2010021381
· 2010
[cited by applicant]
WO WO2010022517
· 2010
[cited by applicant]
WO WO2010026989
· 2010
[cited by applicant]
WO WO2010089127
· 2010
[cited by applicant]
WO WO2010101949
· 2010
[cited by applicant]
WO WO2010108115
· 2010
[cited by applicant]
WO WO2010108268
· 2010
[cited by applicant]
WO WO2010151318
· 2010
[cited by applicant]
WO WO2011140640
· 2011
[cited by applicant]
WO WO2012037298
· 2012
[cited by applicant]
WO WO2012061927
· 2012
[cited by applicant]
WO WO2012062157
· 2012
[cited by applicant]
WO WO2012062759
· 2012
[cited by applicant]
WO WO2012083435
· 2012
[cited by applicant]
WO WO2012117219
· 2012
[cited by applicant]
WO WO2013028715
· 2013
[cited by applicant]
WO WO2013066729
· 2013
[cited by applicant]
WO WO2014023723
· 2014
[cited by applicant]
WO WO2014032187
· 2014
[cited by applicant]
WO WO2014159234
· 2014
[cited by applicant]
WO WO2015083028
· 2015
[cited by applicant]
WO WO2015128333
· 2015
[cited by applicant]
WO WO2015164508
· 2015
[cited by applicant]
WO WO2017001660
· 2017
[cited by applicant]
WO WO2017076900
· 2017
[cited by applicant]
WO WO2017087858
· 2017
[cited by applicant]
WO WO2017087863
· 2017
[cited by applicant]
WO WO2017091818
· 2017
[cited by applicant]
WO WO2017106254
· 2017
[cited by applicant]
WO WO2017144633
· 2017
[cited by applicant]
WO WO2017144635
· 2017
[cited by applicant]
WO WO2017144637
· 2017
[cited by applicant]
WO WO2017144639
· 2017
[cited by applicant]
WO WO2017223243
· 2017
[cited by applicant]
WO WO2018026371
· 2018
[cited by applicant]
WO WO2018109198
· 2018
[cited by applicant]
WO WO2018109202
· 2018
[cited by applicant]
WO WO2018140299
· 2018
[cited by applicant]
WO WO2018141984
· 2018
[cited by applicant]
WO WO2018153507
· 2018
[cited by applicant]
WO WO2018153508
· 2018
[cited by applicant]
WO WO2018154133
· 2018
[cited by applicant]
WO WO2018217558
· 2018
[cited by applicant]
“Acute Leukemia”, Merck Manual (Online Edition), Hematology and Oncology, 6 pages, pp. 1-6, 2013.
[cited by applicant]
Damasio, “Alzheimer's Disease and related dementias”, Cecil Textbook of Medicine, 20th Edition, vol. 2, Edited by Bennett and Plum, pp. 1992-1996, 1996.
[cited by applicant]
Gura, “Cancer Models: Systems for identifying new drugs are often faulty”, Science, vol. 278, pp. 1041-1042, 1997 (5 pages).
[cited by applicant]
Johnson et al., “Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials”, British Journal of Cancer, vol. 84, No. 10, pp. 1424-1431, 2001.
[cited by applicant]
Layzer, “Degenerative diseases of the nervous system”, Cecil Textbook of Medicine, 20th Edition, Section Five, vol. 2, Edited by Bennett and Plum, pp. 2050-2057, 1996.
[cited by applicant]
Pearce et al. “Failure modes in anticancer drug discovery and development”, Cancer Drug Design and Discovery Edited by Stephen Neidle, Chapter 18, pp. 424-435, 2008.
[cited by applicant]
Simone “Oncology: Introduction”, Cecil Textbook of Medicine, 20th Edition, vol. 1, Edited by Bennett and Plum, pp. 1004-1010, 1996.
[cited by applicant]
Bundgaard, H. “Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities”, Design of Prodrugs, (1985), 1 page.
[cited by applicant]
Hulikal, V. “Deuterium Labeled Compounds in Drug Discovery Process”, Abstract, Bioorganics ond Applied Materials Pvt Ltd. (2010), 1 page.
[cited by applicant]
Silverman, “Prodrugs and Drug Delivery Systems”, The Organic Chemistry of Drug Design and Drug Action, (1992), Chapter 8, p. 352-399.
[cited by applicant]
Abdel-Magid, A. F. et al. “Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures” J. Org. Chem., (1996), 61, pp. 3849-3862.
[cited by applicant]
Albertson, N. F. “Alkylation with Non-ketonic Mannich Bases. Aminothiazoles and Pyrrole” J. Am. Chem. Soc., 1948, 70(2), 669-670.
[cited by applicant]
Andres, J. I. et al. “Synthesis, Evaluation, and Radiolabeling of New Potent Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2 as Potential Tracers for Positron Emission Tomography Imaging” J. Med.…
[cited by applicant]
Ansari et al. “The Role of Insulin Resistance and Protein O-GlcNAcylation in Neurodegeneration”, Frontiers in Neuroscience, 2019, vol. 13, Article 473, 9 pages.
[cited by applicant]
Aitipamula, S. et al. “Polymorphs, Salts, and Cocrystals: What's in a Name?”, Crystal Growth & Design, 12(5), 2012, p. 2147-2152.
[cited by applicant]
Apsunde, T.D. et al. “Microwave-Assisted Iridium-Catalyzed Synthesis of Nicotine and Anabasine Derivatives”, Synthesis, vol. 45, No. 15, 2013, pp. 2120-2124.
[cited by applicant]
Aube, J. et al. “Intramolecular Schmidt reaction of alkyl azides”, J. Am. Chem. Soc. 1991, vol. 113, No. 23, p. 8965-8966.
[cited by applicant]
Augustine, J. K. et al. “Propylphosphonic anhydride (T3P®): an efficient reagent for the one-pot synthesis of 1,2,4-oxadiazoles, 1,3,4-oxadiazoles, and 1,3,4-thiadiazoles” Tetrahedron, (2009), 65, pp. 9989-9996.
[cited by applicant]
Bastin, R. J. et al. “Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities”, Organic Process Research & Development, 2000, 4, 427-435.
[cited by applicant]
Berge, S. M. et al. “Pharmaceutical Salts”, Journal of Pharmaceutical Sciences, 1977, 66(1), 1-19.
[cited by applicant]
Biscoe, M. R. et al. “A New Class of Easily Activated Palladium Precatalysts for Facile C—N Cross-Coupling Reactions and Low Temperature Oxidative Addition of Aryl Chlorides”, J. Am. Chem. Soc., 2008, 130, 6686-6687.
[cited by applicant]
Bohnert, T. et al. “Plasma Protein Binding: From Discovery to Development”, J. Pharmaceutical Sciences, 2013, 102, 2953-2994.
[cited by applicant]
Bras, N. F. et al. “Glycosidase inhibitors: a patent review (2008-2013)” Expert Opinion on Therapeutic Patents, vol. 24, No. 8, 2014, pp. 857-874.
[cited by applicant]
Bundgaard, H. “Design and Application of Prodrugs”, from A Textbook of Drug Design and Development Chapter 5, Harwood Academic Publishers, 1991, 113-191.
[cited by applicant]
Calcagno, A. M. “Comparison of Drug Transporter Levels in Normal Colon, Colon Cancer, and Caco-2 Cells: Impact on Drug Disposition and Discovery”, Mol. Pharm., 2006, 3(1), 87-93.
[cited by applicant]
CAS Registry (Online) Nos. 948053-91-6; 540512-02-5; 697229-62-2; 346662-52-0; 345992-64-5 (STN database summary sheets) Sep. 26, 2007.
[cited by applicant]
“Chemical Encyclopedia”, vol. 4, pp. 990-993, 1988. (Machine translation attached).
[cited by applicant]
Chen, Y. et al. “Discovery of new acetylcholinesterase and butyrylcholinesterase inhibitors through structurebased virtual screening”, RSC Advances, 2017, 7(6), 3429-3438.
[cited by applicant]
Chen W. et al. “Redox-Neutral [alpha]-Arylation of Amines”, Organic Letters, vol. 16, No. 3, 2014, pp. 730-732.
[cited by applicant]
Chrovian, C. C. et al.“A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Ca…
[cited by applicant]
Collet, A. “Resolution of Racemates: Did you say ‘Classical?’”, Angewandte Chemie International Edition, 1998, 37(23), 3239-3241.
[cited by applicant]
Dai, W. et al. “Highly Chemoselective and Enantioselective Catalytic Oxidation of Heteroaromatic Sulfides via High-Valent Manganese(IV)-Oxo Cation Radical Oxidizing Intermediates”, ACS Catalysis, 2017, vol. 7, p. 4890-4…
[cited by applicant]
Dassanayaka, S. and Jones, S. “O-GlcNAc and the cardiovascular system”, Pharmacology & Therapeutics, 2014, 142, 62-71.
[cited by applicant]
Database registry (online) Chemical abstract service, Columbus, Ohio, US; Dec. 6, 2011, “Piperazine, 1-[1-(1,3-benzodioxol-5-yl)ethyl]-4-(5-bromo-6-methoxy-2-pyridinyl)-”, Database accession No. 1349611-60-4.
[cited by applicant]
Database Pubchem Compound (Online) NCBI; Jan. 24, 2012, XP002768130, Database accession No. CID 54914491.
[cited by applicant]
Database PubChem Compound (Online) NCBI; May 28, 2009; XP002768131, Database accession No. CID 28798635.
[cited by applicant]
Database PubChem Compound, NCBI; 9. Apr. 2016; XP002768133, Database accession No. CID 118902929.
[cited by applicant]
Database Registry, Chemical Abstracts Service, 2016, CID120907609, 10 pages.
[cited by applicant]
Database Registry, Chemical Abstracts Service, Jan. 11, 2017, XP002768132, Database accession No. 2055841-81-9.
[cited by applicant]
Dorfmueller, H. C. et al. “Cell-Penetrant, Nanomolar O-GlcNAcase Inhibitors Selective against Lysosomal Hexosaminidases”, Chem. Biol., 2010, 17, 1250-1255.
[cited by applicant]
Dubois, B. et al. “Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria”, Alzheimers Dement., 2016, 12, 292-323.
[cited by applicant]
Dubois, B. et al. “Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria”, Lancet Neurol., 2014, 13, 614-629.
[cited by applicant]
Dyatkin, A.B. et al. “Determination of the Absolute Configuration of a Key Tricyclic Component of a Novel Vasopressin Receptor Antagonist by Use of Vibrational Circular Dichroism”, Chirality, 2002, 14, 215-219.
[cited by applicant]
Ellman, J. A et al. “N-tert-Butanesulfinyl Imines: Versatile Intermediates for the Asymmetric Synthesis of Amines” Acc. Chem. Res. (2002), 35, pp. 984-995.
[cited by applicant]
Fleury-Bregeot et al.“Suzuki-Miyaura Cross-Coupling of Potassium Alkoxyethyltri-fluoroborates: Access to Aryl/Heteroarylethyloxy Motifs”, J. Org. Chem. 2012, vol. 77, No. 22, p. 10399-10408.
[cited by applicant]
Fors, B. P. et al. “A Highly Active Catalyst for Pd-Catalyzed Amination Reactions: Cross-Coupling Reactions Using Aryl Mesylates and the Highly Selective Monoarylation of Primary Amines Using Aryl Chlorides”, J. Am. Che…
[cited by applicant]
Frehel, D. et al. “New synthesis of 5,6,7,8-tetrahydro-4H-thieno[2,3-d]azepine”, Journal of Heterocyclic Chemistry, 1985, vol. 22, p. 1011-1016.
[cited by applicant]
Frings, M. et al. “Sulfoximines from a Medicinal Chemist's Perspective: Physicochemical and in vitro Parameters Relevant for Drug Discovery”, European Journal of Medicinal Chemistry, 2017, 126, 225-245.
[cited by applicant]
Goho, A. “Tricky Business”, Science News, 2004, 166(8), 122-124.
[cited by applicant]
Gong et al. “O-GlcNAcylation: A regulator of tau pathology and neurodegeneration”, Alzheimer's & Dementia, 2016, vol. 12, p. 1078-1089.
[cited by applicant]
Golub, T. R. et al. “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring”, Science, 1999, 286, 531-537.
[cited by applicant]
Gould, P. L. “Salt selection for basic drugs”, International Journal of Pharmaceutics, 1986, 33, 201-217.
[cited by applicant]
Graham, D. L. et al. “Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy”, Neuropharmacology, 2014, 79, 307-313.
[cited by applicant]
Gujjar, R. et al. “Lead Optimization of Aryl and Aralkyl Amine-Based Triazolopyrimidine Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity in Mice”, J. Med. Chem., 2011, 54 (11),…
[cited by applicant]
Haleblian, J.; McCrone, W. “Pharmaceutical Applications of Polymorphism”, J. Pharm. Sci., 1969, 58(8), 911-929.
[cited by applicant]
Haleblian, J. “Characterization of Habits and Crystalline Modification of Solids and Their Pharmaceutical Applications”, J. Pharm. Sci., 1975, 64(8), 1269-1288.
[cited by applicant]
Hemming, K. “Product Class 6: 1,2,4-Oxadizoles” Science of Synthesis, (2004), 13(6), pp. 127-184.
[cited by applicant]
Jakopin, Z. et al. “Recent Advances in the Synthesis of 1,2,4- and 1,3,4-Oxadiazoles” Current Organic Chemistry, (2008), 12(10), pp. 850-898.
[cited by applicant]
Kempson, J. “Name Reactions in Heterocyclic Chemistry II” John Wiley & Sons. Eds. Jie Jack Li and E. J. Corey, (2011), pp. 299-308.
[cited by applicant]
Kim, E. J. et al. “Enzymatic characterization of O-GlcNAcase isoforms using a fluorogenic GlcNAc substrate”, Carbohydrate Research, 2006, 341(8), p. 971-982.
[cited by applicant]
Kim, E. J. “Chemical Arsenal for the Study of O-GlcNAc”, Molecules, 2011, vol. 16, p. 1987-2022.
[cited by applicant]
Kim et al. “Discovery of β-Arrestin Biased Ligands of 5-HT7R”, Journal of Medicinal Chemistry, 2019, vol. 61, p. 7218-7233.
[cited by applicant]
Knapp, S. et al. “An Allosamizoline/ Glucosamine Hybrid NAGase Inhibitor”, Synlett, 1997, 5, 435-436.
[cited by applicant]
Lefebvre, T. “Recall sugars, forget Alzheimer's”, Nature Chemical Biology, 2012, 8(4), 325-326.
[cited by applicant]
Legros, J. et al. “Applications of Catalytic Asymmetric Sulfide Oxidations to the Syntheses of Biologically Active Sulfoxides”, Adv. Synth. Catal., 2005, 347, 19-31.
[cited by applicant]
Liu, X. et al. “Rational Use of Plasma Protein and Tissue Binding Data in Drug Design”, J. Med. Chem. 2014, 57, 8238-8248.
[cited by applicant]
Marwaha, A. et al. “Bioisosteric Transformations and Permutations in the Triazolopyrimidine Scaffold To Identify the Minimum Pharmacophore Required for Inhibitory Activity against Plasmodium falciparum Dihydroorotate De…
[cited by applicant]
Mariappa, D. et al. “A mutant O-GlcNAcase as a probe to reveal global dynamics of the Drosophila O-GlcNAc developmental proteome”, Biochem J., 2015, 470(2), 255-262.
[cited by applicant]
Marotta, N. P. et al., “O-GlcNAc modification blocks the aggregation and toxicity of the Parkinson's disease associated protein α-synuclein”, Nat. Chem, 2015, 7(11), 913-920.
[cited by applicant]
Masuda, N. et al. “Studies of nonnucleoside HIV-1 reverse transcriptase inhibitors. Part 1: Design and synthesis of thiazolidenebenzenesulfonamides”, Bioorg. Med. Chem., 2004, 12, 6171-6182.
[cited by applicant]
Merchant, R. R. et al. “Regioselective Preparation of Saturated Spirocyclic and Ring-Expanded Fused Pyrazoles”, J. Org. Chem. 2014, vol. 79, No. 18, p. 8800-8811.
[cited by applicant]
Micksch, M. et al. “Synthesis of 1,2-Diaryl- and 1-Aryl-2-alkylimidazoles with Sterically Demanding Substituents”, Eur J. Org. Chem. 2013, Issue 27, p. 6137-6145.
[cited by applicant]
Miller III et al. “Design of e-pharmacophore models using compound fragments for the trans-sialidase of Trypanosoma cruzi: screening for novel inhibitor scaffolds”, Journal of Molecular Graphics and Modelling, vol. 45, …
[cited by applicant]
Mittur A. “Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders” Current Drug Therapy (2011), 6, pp. 17-34.
[cited by applicant]
Moradi-Afrapoli, F. et al. “In vitro α-glucosidase inhibitory activity of phenolicconstituents from aerial parts of Polygonum hyrcanicum”, DARU Journal of Pharmaceutical Sciences, 2012, 20(1), 37, 6 pages.
[cited by applicant]
Motiwala, H.F. et al. “Remodeling and Enhancing Schmidt Reaction Pathways in Hexafluoroisopropanol”, J. Org. Chem. 2016, vol. 81, No. 8, p. 1593-1609.
[cited by applicant]
Nandi, A. et al. “Global Identification of O-GlcNAc-Modified Proteins”, Anal. Chem., 2006, 78, 452-458.
[cited by applicant]
Nelson, P. T. et al. “Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature”, J. Neuropathol. Exp. Neurol., 2012, 71(5), 362-381.
[cited by applicant]
Nettekoven, M. et al. “Synthetic Access to 2-Amido-5-aryl-8-methoxy-triazolopyridine and 2-Amido-5-morpholino-8-methoxy-triazolopyridine Derivatives as Potential Inhibitors of the Adenosine Receptor Subtypes”, Synthesis…
[cited by applicant]
Obach, R. S. “Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: and examination of in vitro half-life approach and nonspecific binding to microsomes”, Drug. Metab. Disp…
[cited by applicant]
Okamura, H. et al. “Rhodium-Catalyzed Imination of Sulfoxides and Sulfides: Efficient Preparation of N-Unsubstituted Sulfoximines and Sulfilimines”, Organic Letters, 2004, 6, 1305-1307.
[cited by applicant]
O'Mahony, G. E. et al. “Synthesis of enantioenriched sulfoxides” Arkivoc, 2011, 1-110.
[cited by applicant]
Orain, D. et al. “Synthesis of Orthogonally Protected 2,6-Diazaspiro[3.5]nonane and 2,6-Diazaspiro[3.4]octane Analogues as Versatile Building Blocks in Medicinal Chemistry”, Synlett, 2015, 26(13), 1815-1818.
[cited by applicant]
Papillon, J. P. N. et al. “Discovery of N-[5-(6-Chloro-3-cyano-1-methyl-1H-indol-2-y1)-pyridin-3-ylmethyl]-ethanesulfonamide, a Cortisol-Sparing CYP11B2 Inhibitor that Lowers Aldosterone in Human Subjects”, J. Med. Chem…
[cited by applicant]
Park, M.-J et al. “High Glucose-induced O-GlcNAcylated Carbohydrate Response Element-binding Protein (ChREBP) Mediates Mesangial Cell Lipogenesis and Fibrosis”, J. Biol. Chem., 2014, 289, 13519-13530.
[cited by applicant]
Reddy et al. “Synthesis of Chiral Benzimidazole-Pyrrolidine Derivatives and their Application in Organocatalytic Aldol and Michael Addition Reactions”, Synthetic Communications, vol. 37, No. 24, 2007, pp. 4289-4299.
[cited by applicant]
Rouhi, A. M. et al. “The Right Stuff: From Research and Development to the Clinic, Getting Drug Crystals Right is Full of Pitfalls.” Chem. Eng. News. (2003):32-35.
[cited by applicant]
Ryan et al. “The O-GlcNAc modification protects against protein misfolding and aggregation in neurodegenerative disease”, ACS Chemical Neuroscience, 2019, 17 pages.
[cited by applicant]
Santacruz, K. et al. “Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function”, Science, 2005, 309, 476-481.
[cited by applicant]
Serajuddin, A. T. M. “Salt formation to improve drug solubility”, Advanced Drug Delivery Reviews, 2007, 59(7), 603-616.
[cited by applicant]
Shan, X. et al. “Reduced protein O-glycosylation in the nervous system of the mutant SODI transgenic mouse model of amyotrophic lateral sclerosis”, Neuroscience Letters, 2012, 516, 296-301.
[cited by applicant]
Shen, Q. et al. “Hydroxycoumarin Derivatives: Novel and Potent α-Glucosidase Inhibitors”, J. Med. Chem., 2010, 53(23), 8252-8259.
[cited by applicant]
Shirude, P. et al. “Lead Optimization of 1,4-Azaindoles as Antimycobacterial Agents”, J. Med. Chem., 2014, 57(13), 5728-5737.
[cited by applicant]
Sippy, K. B. et al. “Preparation and characterization of N-(3-pyridinyl) spirocyclic diamines as ligands for nicotinic acetylcholine receptors”, Bioorganic & Med. Chemistry Letters, 2009, 19(6), 1682-1685.
[cited by applicant]
Skedelj, V. et al. “Discovery of the first inhibitors of bacterial enzyme D-aspartate ligase from Enterococcus faecium (Asl
[cited by applicant]
Song, S. et al. “Efficient and Practical Oxidative Bromination and Iodination of Arenes and Heteroarenes with DMSO and Hydrogen Halide: A Mild Protocol for Late-Stage Functionalization”, Org. Lett., 2015, 17(12), 2886-2…
[cited by applicant]
Sperling, R. A. et al. “Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's dis…
[cited by applicant]
Spillantini, M. G.; Goedert, M. “Tau pathology and neurodegeneration”, Lancet Neurol., 2013, 12, 609-622.
[cited by applicant]
Tamura, B. K. et al. “Weight Loss in Patients with Alzheimer's Disease” J. Nutrition for the Elderly (2008), 26(3-4), pp. 21-38.
[cited by applicant]
Tan, H. et al. “Rational Screening Approach for Classical Chiral Resolution under Thermodynamic Equilibrium: A Case Study of Diphenyl-Substituted N-Methyl-Piperazine”, Organic Process Research and Development, 2011, 15(…
[cited by applicant]
Tanuwidjaja, J. et al. “One-Pot Asymmetric Synthesis of Either Diastereomer of tert-Butanesulfinyl-protected Amines from Ketones”, J. Org. Chem. 2007, 72, 626-629.
[cited by applicant]
The U. S. Pharmacopeia 38—National Formulary 35 Chapter 941, Characterization of crystalline and partially crystalline solids by X-ray powder diffraction (XRPD) Official May 1, 2015, 427-431.
[cited by applicant]
Thiel, O. R. et al. “Practical Synthesis of a Vanilloid Receptor-1 Antagonist” J. Org. Chem., (2008), 73(9), pp. 3508-3515.
[cited by applicant]
Trapannone, R. et al. “O-GlcNAc transferase inhibitors: current tools and future challenges”, Biochemical Society Transactions, 2016, 44(1), 88-93.
[cited by applicant]
Vasudevan, A. et al. “Identification of aminopiperidine benzamides as MCHrl antagonists”, Bioorganic & Medicinal Chemistry Letters, 2005, 15(14), 3412-3416.
[cited by applicant]
Volpe, D. A. “Application of Method Suitability for Drug Permeability Classification”, The AAPS Journal, 2010, 12(4), 670-678.
[cited by applicant]
Wall, G. M. “Pharmaceutical Applications of Drug Crystal Studies”, Pharm. Manuf., 1986, 3, 32-42.
[cited by applicant]
Wang, Z. et al. “Enrichment and Site Mapping of O-Linked N-Acetylglucosamine by a Combination of Chemical/Enzymatic Tagging, Photochemical Cleavage, and Electron Transfer Dissociation Mass Spectrometry”, Mol. Cell Prote…
[cited by applicant]
Waterman, K. C. “Improved Protocol and Data Analysis for Accelerated Shelf-Life Estimation of Solid Dosage Forms”, Pharm. Res., 2007, 24(4), 780-790.
[cited by applicant]
Weinberg, K. et al. “Synthesis and differential functionalisation of pyrrolidine and piperidine based spirodiamine scaffolds”, Tetrahedron, 2013, 69(23), 4694-4707.
[cited by applicant]
Wermuth, C. G. et al. “Designing Prodrugs and Bioprecursors I: Carrier Prodrugs”, The Practice of Medicinal Chemistry: Chapter 31, Academic Press, 1996, 671-696.
[cited by applicant]
Wiessner et al. “A novel non-carbohydrate o-linked beta-n-acetylglucosaminidase inhibitor increases tau o-glenacylation In vivo”, Abstracts of the Annual Meeting of the Society for Neuroscience, Society for Neuroscience…
[cited by applicant]
Williams, D. R. et al. “Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome”, Brain, 2007, 130, 1566-1576.
[cited by applicant]
Xu, Daqian et al. “The synthesis of chiral tridentate ligands from L-proline and their application in the copper(II)-catalyzed enantioselective Henry reaction”, Tetrahedron Asymmetry, vol. 28, No. 7, 2017, p. 954-963.
[cited by applicant]
Hiroshi Yamanaka, Hiroshi Miyazaki and Naomi chi Murakami, Chemical Abstract, “Separation of optical isomers”, Japan, Gakkai Shopping Santa, 1989, 21 pages.
[cited by applicant]
Yoshida, M. et al. “Study of biodegradable copoly(L-lactic acid/glycolic acid) formulations with controlled release of Z-100 for application in radiation therapy”, Int. J. Pharm., 1995, 115, 61-67.
[cited by applicant]
Youngdale et al. “Synthesis and pharmacological activity of 3-(2-pyrrolidinyl)indoles”, Journal of Medicinal Chemistry, vol. 7, Jul. 1, 1964, pp. 415-427.
[cited by applicant]
Yu, Y. J. et al. “One-Pot Synthesis of Spirocyclic or Fused Pyrazoles from Cyclic Ketones: Calcium Carbide as the Carbon Source in Ring Expansion”, Org. Chem. 2017, vol. 82, No. 18, p. 9479-9486.
[cited by applicant]
Yuzwa, S. A. et al. “Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody”, Amino Acids, 2011, 40, 857-868.
[cited by applicant]
Yuzwa, S. A. et al. “A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo”, Nat. Chem. Biol., 2008, 4(8), 483-490.
[cited by applicant]
Yuzwa et al. “O-GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer's disease and beyond”, Chem. Soc. Review, 2014, 20 pages.
[cited by applicant]
Yuzwa, S. A. et al. “Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation”, Nat. Chem. Biol., 2012, 8(4), 393-399.
[cited by applicant]
Zenzola, M. et al. “Transfer of Electrophilic NH Using Convenient Sources of Ammonia: Direct Synthesis of NH Sulfoximines from Sulfoxides”, Angew. Chem. Int. Ed., 2016, 55, 7203-7207.
[cited by applicant]
Zhang, Chen et al. “Nontraditional Reactions of Azomethine Ylides: Decarboxylative Three-Component Couplings of [alpha]-Amino Acids”, Journal of the American Chemical Society, vol. 132, No. 6, 2010, pp. 1798-1799.
[cited by applicant]
Smith, P.W. et al. “New spiropiperidines as potent and selective non-peptide tachykinin NK
[cited by applicant]
Addis et al. “Efficient Conversion of Astrocytes to Functional Midbrain Dopaminergic Neurons Using a Single Polycistronic Vector”, (2011) PloS ONE: e28719 (8 pages).
[cited by applicant]
Alenghat T. et al. “Histone deacetylase 3 coordinates commensal bacteria-dependent intestinal homeostasis”, (2013) Nature 504:153-157.
[cited by applicant]
Boxer et al. “Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial”, Lancet Neurol. 2014;13(7):676-85.
[cited by applicant]
Boxer et al., “Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches”, Lancet 16:552-563, 2017.
[cited by applicant]
Chen et al. “Protective Effects of Glucosamine on Oxidative-Stress and Ischemia/Reperfusion-Induced Retinal Injury”, (2015), Invest Ophthalmol. Vis Sci. 56(3):1506-1516.
[cited by applicant]
Co-pending U.S. Appl. No. 18/570,861, inventors Beher; Dirk et al., filed on Dec. 15, 2023.
[cited by applicant]
Fleming et al. “Early and Progressive Sensorimotor Anomalies in Mice Overexpressing Wild-Type Human alpha-Synuclein”, 2004, The Journal of Neuroscience, 24 (42):9434-40.
[cited by applicant]
Gilbert S. et al. “Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation”, (2012) EMBO Mol. Med.4: 109-124.
[cited by applicant]
Han et al. “Direct Reprogramming of Fibroblasts into Neural Stem Cells by Defined Factors”, (2012) Cell Stem Cell 10: 465-472.
[cited by applicant]
Hinz et al., “Molecular Genetics of Neurodegenerative Dementias”, Cold Spring Harbor Perspectives in Biology, 2017, 9:a023705 (23 pages).
[cited by applicant]
Höglinger et al., “Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy”, Nature Genetics 43 :699-705, 2011.
[cited by applicant]
Höglinger et al. (2017) “Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials”, Movement Disorders, 32(6):842-852.
[cited by applicant]
Höglinger et al. (2017) “Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria”, Movement Disorders, 32:853-64.
[cited by applicant]
Kim J. et al. “Direct reprogramming of mouse fibroblasts to neural progenitors”, (2011) Proc Natl Acad Sci USA 108(19):7838-7843.
[cited by applicant]
Kuhn J. et al. “Deep Brain Stimulation of the Nucleus Basalis of Meynert in Early Stage of Alzheimer's Dementia”, (2015) Brain Stimulation 8:838-839.
[cited by applicant]
Levine et al. (2019) “α-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson's disease”, Proc. Natl. Acad. Sci. USA 116(5):1511-1519.
[cited by applicant]
Lim et al. “Generation of Dopamine Neurons from Rodent Fibroblasts through the Expandable Neural Precursor Cell Stage”, (2015) J. Biol. Chem. 290:17401-17414.
[cited by applicant]
Lozano et al. (2016) “A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer's Disease”, Journal of Alzheimer's Disease, 54 :777-787.
[cited by applicant]
Lujan E. et al. “Direct conversion of mouse fibroblasts to self-renewing, tripotent neural precursor cells”, (2012) Proc Natl Acad Sci USA 109 :2527-2532.
[cited by applicant]
Matsui T. et al. “Neural Stem Cells Directly Differentiated from Partially Reprogrammed Fibroblasts Rapidly Acquire Gliogenic Competency”, (2012) Stem Cells 30: 1109-1119.
[cited by applicant]
Mayer, P. “On the Staining of Mucus”, (1897), Mitt. Zool. Stn. Neape.,12, p. 303-330.
[cited by applicant]
Mirzadeh Z. et al. “The rationale for deep brain stimulation in Alzheimer's disease”, (2016) J. Neural Transm (Vienna) 123: 775-783.
[cited by applicant]
Opposition Arguments, Notice of Opposition, Indian Pharmaceutical Alliance, in Patent Application No. 202127010343 dated Nov. 3, 2021 filed by Asceneuron S.A. (Applicant), dated Feb. 6, 2024, 26 pages.
[cited by applicant]
Paul S. et al. “Evaluation of a PET Radioligand to Image O-GlcNAcase in Brain and Periphery of Rhesus Monkey and Knock-Out Mouse”, J. Nucl. Med. 2019, 60(1), 129-134.
[cited by applicant]
Racine R.J. “Modification of Seizure Activity by Electrical Stimulation: I. After-Discharge Threshold”, Electroencephalography and Clinical Neurophysiology 32(3), 269-279 (1972).
[cited by applicant]
Rockenstein E, et al. “Differential Neuropathological Alterations in Transgenic Mice Expressing alpha-synuclein From The Platelet-derived Growth Factor and Thy-1 Promoters”, Journal of Neuroscience Research 68:568-578 (…
[cited by applicant]
Sanchez et al. “Human and rodent temporal lobe epilepsy is characterized by changes in OGlcNAc homeostasis that can be reversed to dampen epileptiform activity”, (2019) Neurobiology of Disease 124: 531-543.
[cited by applicant]
Sankar T et al. “Deep Brain Stimulation Influences Brain Structure in Alzheimer's Disease”, (2015) Brain Stimulation 8:645-654.
[cited by applicant]
Sheng C. et al. “Direct reprogramming of Sertoli cells into multipotent neural stem cells by defined factors” (2012) Cell Res 22: 208-218.
[cited by applicant]
Stamelou M et al. (2016) “Power calculations and placebo effect for future clinical trials in progressive supranuclear palsy”, Mov Disord. 31 (5):742-747.
[cited by applicant]
Tolosa et al. (2014) “A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy”, Movement Disorders 29(4):470-478.
[cited by applicant]
Vierbuchen T. et al. “Direct conversion of fibroblasts to functional neurons by defined factors”, (2010) Nature 463:1035-1041.
[cited by applicant]
Wahlund et al. (2001) “A new rating scale for age-related white matter changes applicable to MRI and CT”, Stroke, 32(6):1318-1322.
[cited by applicant]
Zhang S. Z. et al. “Modeling Neurological Disease by Rapid Conversion of Human Urine Cells into Functional Neurons”, (2016) Stem Cells International, 2016: 2452985 (9 pages).
[cited by applicant]
Zhao J. et al. “Neuronal Transcription Factors Induce Conversion of Human Glioma Cells to Neurons and Inhibit Tumorigenesis”, (2012) PLoS ONE7:5e41506 (11 pages).
[cited by applicant]
Zhao M, et al. “Deficiency in intestinal epithelial O-GlcNAcylation predisposes to gut inflammation”, (2018) EMBO Mol. Med. 10: e8736 (18 pages).
[cited by applicant]
U.S. Appl. No. 18/062,295, filed Dec. 6, 2022.
[cited by applicant]
U.S. Appl. No. 16/078,159, filed Aug. 21, 2018.
[cited by applicant]
U.S. Appl. No. 16/877,284, filed May 18, 2020.
[cited by applicant]
U.S. Appl. No. 16/488,139, filed Aug. 22, 2019.
[cited by applicant]
U.S. Appl. No. 16/640,280, filed Feb. 19, 2020.
[cited by applicant]
U.S. Appl. No. 17/269,811, filed Feb. 19, 2021.
[cited by applicant]
U.S. Appl. No. 17/269,814, filed Feb. 19, 2021.
[cited by applicant]
U.S. Appl. No. 17/269,817, filed Feb. 19, 2021.
[cited by applicant]
U.S. Appl. No. 17/269,823, filed Feb. 19, 2021.
[cited by applicant]
U.S. Appl. No. 17/431,736, filed Aug. 18, 2021.
[cited by applicant]
CAS Registry Entry: 890335-15-6 (STN data summary sheet). Entered STN: Jul. 3, 2006, 1 pg.
[cited by applicant]
Cited By (1)